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Abstract 
Background: Heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) is closely related to tumour occurrence 
and development, oncogene expression, apoptosis inhibition and invasion and metastasis capacities. However, its 
function in the epithelial–mesenchymal transition (EMT) of pancreatic cancer is not fully understood.
Methods: By comparing various wild-type pancreatic cancer cell lines, we determined which have a higher expres-
sion level of HNRNPA2B1 accompanied by the higher expression of N-cadherin and vimentin and lower expression of 
E-cadherin. Therefore, to elucidate the role of HNRNPA2B1 in EMT, we generated models of HNRNPA2B1 knockdown 
and overexpression in different types of pancreatic cancer cell lines (MIA Paca-2, PANC-1 and Patu-8988) and exam-
ined changes in expression of EMT-related factors, including CDH1, CDH2, vimentin and snail.
Results: The results show that HNRNPA2B1 promotes EMT development by down-regulating E-cadherin and up-
regulating N-cadherin and vimentin, and also stimulates the invasion capacity and inhibits viability in human pancre-
atic cancer cell lines, the similar results in vivo experiments. Moreover, we found that HNRNPA2B1 likely regulates EMT 
progression in pancreatic carcinoma via the ERK/snail signalling pathway.
Conclusions: The results of this work suggest that HNRNPA2B1 inhibition has potential antitumour effects, which 
warrants in-depth investigation.
Keywords: Epithelial–mesenchymal transition, HNRNPA2B1, ERK/snail, Pancreatic cancer
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pancreatic carcinoma, which is nearly almost always 
fatal, is the fourth leading cause of cancer-related death 
worldwide, with fewer than 7% of patients surviving 
more than 5  years [1]. Chemotherapy (mainly based on 
gemcitabine and capecitabine) and radiation therapy 
remain the mainstay of treatment for pancreatic cancer, 
with poor efficacy in terms of extending patient survival 
[2, 3]. Additionally, although the curative effect is better, 
only 15% of patients who undergo surgery survive more 
than 5 years [4, 5]. In view of this dismal outcome, to ena-
ble treatment of this deadly disease with new druggable 
targets, there is an urgent need to thoroughly understand 
the molecular mechanisms of pancreatic cancer patho-
physiology and development.
Recent studies have shown that heterogeneous nuclear 
ribonucleoproteins A2B1 (HNRNPA2B1), two structur-
ally homologous proteins belonging to the hnRNP family, 
play important roles in normal development as well as in 
cancer processes in eukaryotic cells [6]. Indeed, elevated 
HNRNPA2B1 levels in tumours accelerate pre-mRNA 
processing via RNA binding, indicating the critical role of 
HNRNPA2B1 in the development of carcinoma. Recent 
work shows that the epithelial–mesenchymal transition 
(EMT), a process in which epithelial cells transform into 
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cells with mesenchymal phenotypes, may be regulated 
by HNRNPA2B1. During EMT in tumour cells, up-reg-
ulation of vimentin and N-cadherin and down-regulation 
of E-cadherin (cell–cell adhesion molecules) promote 
cell invasion and metastasis in various cancers, includ-
ing pancreatic cancer [7–10]. Other factors also directly 
or indirectly trigger EMT, including claudins, occludin, 
fibronectin, twist1, ZEB2 and snail [11–15]. Zhou et  al. 
[16] indicated that HNRNPAB induces EMT and pro-
motes metastasis of hepatocellular carcinoma by tran-
scriptionally activating snail [16], and Barcelo et al. [17] 
showed that HNRNPA2B1 plays a key role in Kras-muta-
tion associated pancreatic cancer [17]. Based on these 
findings, HNRNPA2B1 might play an important role in 
EMT during tumour development.
To date, however, no study has reported on the role 
of HNRNPA2B1 in EMT in pancreatic cancer. Thus, we 
aimed to determine the roles and potential application 
of HNRNPA2B1 in the EMT of pancreatic cancer by 
exploring the impact of HNRNPA2B1 knockdown and 
overexpression on EMT and the subsequent invasion 
and metastasis of pancreatic cancer cells. Furthermore, 
we here demonstrate the possibility that HNRNPA2B1 
regulates and controls EMT in pancreatic cancer cells 
through the ERK/snail pathway. In conclusion, we con-




The human pancreatic cancer cell lines used in this study 
include Patu-8988, MIA Paca-2 and PANC-1. The MIA 
Paca-2 and PANC-1 lines were obtained from the Insti-
tute of Biochemistry and Cell Biology, the Chinese Acad-
emy of Science (Shanghai, People’s Republic of China), 
and Patu-8988 cells were provided by Genechem (Shang-
hai, China). Patu-8988 cells were cultured in RPMI-1640 
medium, and MIA Paca-2 and PANC-1 cells were cul-
tured in DMEM. All media contained 10% foetal bovine 
serum, penicillin (100 U/mL), and streptomycin (100 μg/
mL), and the cells were incubated at 37 °C with 5% CO2. 
Cell were harvested and passaged at approximately 
80–100% confluence using phosphate-buffered saline 
(PBS) with 0.25% trypsin and 0.01% EDTA.
Reagents and antibodies
Antibodies against HNRNPA2B1, E-cadherin, vimentin, 
N-cadherin, MMP7, MMP9, ERK1/2 and phosphoryl-
ated proteins were purchased from Abcam (Cambridge, 
USA). An antibody against β-actin was purchased from 
Bio-world Technology (St Louis Park, MN, USA). An 
antibody against snail was purchased from Cell Signal-
ing Technology (Danvers, USA). Foetal bovine serum 
(FBS) was purchased from Sigma Chemical (St Louis, 
MO, USA). Roswell Park Memorial Institute (RPMI)-
1640 medium, Dulbecco’s Modified Eagle’s Medium 
(DMEM), and trypsin were purchased from GIBCO 
(Grand Island, NY, USA). ERK-inhibitor (GSK2656157) 
was purchased from MedChem Express (New Jersey, 
USA) and gemcitabine was purchased from Jkchem 
(Shanghai, China).
Knockdown and overexpression of HNRNPA2B1
A lentivirus plasmid containing a short hairpin RNA 
(shRNA) for HNRNPA2B1(KH)and its negative control 
(NKH) and a lentivirus plasmid containing HNRNPA2B1 
driven by the CMV promoter (OH) and its negative 
control (NOH) were designed and produced by Gene-
chem (Shanghai, China). For transfection, MIA Paca-
2, PANC-1 and Patu-8988 cells were seeded in 6-well 
plates at 5 × 104 cells and allowed to attach until nearly 
30–40% confluent. After removal of the culture medium, 
the plates were washed three times with PBS, and lenti-
virus and 50  μg/mL polybrene was added to each plat. 
After 12 h of transfection, the transfection medium was 
replaced with standard medium. Cells were harvested for 
passaging or testing when they occupied 80% of the plate. 
All procedures were performed using biohazard safety 
equipment.
Western blot analysis
Protein was extracted by adding RIPA buffer (Beyotime, 
Shanghai, China) with protease inhibitor (Beyotime, 
Shanghai, China) and phosphatase inhibitor (Roche 
Diagnostics GmbH, Mannheim, Germany). The final 
protein lysate was centrifuged, and the supernatant was 
collected. BCA (Beyotime, Shanghai, China) was used to 
measure the protein concentration. After denaturing, the 
protein mixture was separated using a 10% polyacryla-
mide gel; a prestained protein marker was included. The 
separated proteins were transferred to polyvinylidene dif-
luoride (PVDF) membranes, which were blocked with 5% 
skim milk in Tris-buffered saline (10 mmol/L Tris–HCl, 
pH 8.0, containing 150  mmol/L NaCl and 0.1% Tween-
20) for 2 h at room temperature before being incubated 
at 4 °C overnight with primary antibodies diluted in First 
Ab Dilute. The membranes were then incubated with 
horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Bio-world Technology, MN, USA) for 2 h at 
room temperature after washing with TBST. The densi-
ties of the protein bands were recorded and measured by 
AlphaEaseFC (STandalone).
RNA extraction and quantitative real‑time PCR analysis
When the cells were approximately 90% confluent, total 
RNA was extracted using TRzol Reagent (Ambion, 
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Carlsbad, California, USA) according to the manufac-
turer’s instructions. To obtain cDNA, reverse transcrip-
tion was performed with RevertAid First Strand cDNA 
Synthesis Kit(Thermo, Manassas, USA). qRT-PCR was 
performed with SYBR Green Master (Biosystems, Fos-
ter City, CA, USA) using a 7500 Real-Time PCR System 
(Applied Biosystems, Foster City, USA). β-Actin was 
amplified as an internal standard, and ΔCt values were 
used for analysis of the quantitative real-time PCR data. 
Polymerase chain reaction (PCR) primers were pur-
chased from Synbio Tech (Jiangsu, People’s Republic of 
China); the sequences are listed in Table 1.
Cell viability assay
The different cell models were plated into 96-well plates 
containing 1 mL 10% FBS medium at a density of 10,000 
cells per well and incubated for 24  h. The cells were 
starved in FBS-free medium for 12  h when the cells in 
each well reached 70% confluence. The medium was dis-
carded, and the cells were washed once with PBS before; 
100 μL FBS-free medium containing 10 μL Cell Counting 
Kit 8 (CCK8; Dojindo, Kuma-moto, Japan) solution was 
added to each well and incubated for 1–2 h. Cell viability 
is expressed as the fold change in absorbance at 490 nm 
for each well, as measured using a microplate reader 
(BioTek, Winooski, VT, USA).
Cell invasion assay
Transwell Permeable Supports (Costar, Kennebunk, 
USA) with matrigel Basement Membrane Matrix (Corn-
ing, Franklin Lake, NJ, USA) bedding were used with an 
8  μm porosity polyethylene terephthalate membrane. 
Cells (5  ×  104) were starved overnight and added to 
the upper chamber in 200 μL FBS-free medium; 500 μL 
RPMI-1640 (for Patu-8988 cells) or DMEM (for PANC-1 
and MIA Paca-2 cells) with 10% FBS was added to the 
lower compartment as a chemoattractant. The cells were 
incubated for 24  h, and the filters were washed three 
times with PBS, fixed with 4% paraformaldehyde for 
30 min, stained with 4 g/L crystal violet for 15 min and 
washed twice with PBS. The cells on the upper surface of 
the filter were gently scraped off. The stained cells in ran-
domly selected fields were observed and counted using a 
200× inverted microscope.
Cell cycle analysis
The cell cycle analysis was measured using the Propid-
ium iodide Kit for Flow Cytometry (Multiscience, Hang-
zhou, Zhejiang, China), according to the manufacturer’s 
instructions. After the treatments, cell cycle analysis was 
measured using a Thermo Attune and analyzed using the 
ModFit LT2.0 software (Coulter, Miami, FL).
Establishment of the xenografted tumor model in nude 
mice
Athymic nude mice (BALB/C-nu/nu, 6–8  weeks old, 
female) were gained from the Animal Center of Chinese 
Academy of Science (Shanghai, China) and fed under 
specific pathogen-free conditions in the laboratory ani-
mal center of Wenzhou Medical University (Wenzhou, 
Zhejiang, China). We established a pancreatic xeno-
grafted tumor model through subcutaneous injection 
of 1 ×  107 pancreatic cancer cells per mouse. After the 
treatments, we observe the growth rate of tumor volume 
and the change of weight on each mice. All researches 
involving animals were approved by the Animal Ethics 
Committee of Wenzhou Medical University.
Statistical analysis
Data are expressed as the mean ±  standard error of the 
mean (SEM) for at least three independent experiments. 
Analysis of variance was utilised to distinguish differ-
ences in each group. A value of P < 0.05 was considered 
to be statistically significant. All analyses were performed 
using SPSS 16.0 software (IBM, USA).
Results
HNRNPA2B1 expression was associated with the 
mesenchymal phenotype in pancreatic cancer cell lines
We first explored the relationship between HNRNPA2B1 
and EMT in wild-type human pancreatic cancer cell lines 
(Patu-8988, MIA Paca-2 and PANC-1) by qRT-PCR and 
Western blotting and we found highest N-cadherin and 
HNRNPA2B1 expression and lowest E-cadherin in the 
Patu-8988 cell line compared to the Panc-1 and MIA 
Paca-2 cell line. The expression levels of HNRNPA2B1 in 
Table 1 The sequences of  the primers used for  quantita-
tive real-time PCR
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the different cells was directly correlated to the levels of 
N-cadherin and vimentin and inversely correlated to the 
levels of E-cadherin (P < 0.05; Fig. 1a, b).
HNRNPA2B1 regulated cell viability and EMT in pancreatic 
cancer cell lines
We then generated cell models of HNRNPA2B1 knock-
down and overexpression and examined accompanying 
changes in cell viability. All cell lines were treated with 
trypsinisation, and the cells in suspension were assayed 
using CCK8 after 24  h of incubation. Non-transfected 
pancreatic carcinoma cell lines were used as controls. 
The notable linearity of the graph revealed the lowest 
viability for the HNRNPA2B1 knockdown cells. Moreo-
ver, the non-transfected cells and the HNRNPA2B1 lenti-
virus negative control cells showed viability between the 
knockdown and overexpressing cells, with no statistical 
significance between them (P > 0.05; Fig. 1c). The level of 
HNRNPA2B1 expression was correlated with cell viabil-
ity. To investigate if the cell cycle analysis is conforming 
to the consequence of CCK8 in the pancreatic cancer 
cell lines with HNRNPA2B1 knockdown or overexpres-
sion were generated by lentiviral gene delivery system. 
We were able to detect the G0G1 cell cycle arrest of Patu-
8988-KH, Panc-1-KH and MIA Paca-2-KH cells and the 
S-Phase cell cycle increased of Patu-8988-OH, Panc-
1-OH and MIA Paca-2-OH cells, but no significance dif-
ference was found in the G2M cell cycle of those cells 
(Fig.  2). So we concluded that HNRNPA2B1 could pro-
mote the proliferation of pancreatic cancer cells.
We then sought insight into the relationship between 
HNRNPA2B1 and EMT. In addition to HNRNPA2B1, 
we also analysed EMT markers (E-cadherin, N-cadherin 
and vimentin). Western blotting assays showed that the 
protein levels of HNRNPA2B1 were decreased to 66% 
in Patu-8988, 52% in MIA Paca-2 and 50% in PANC-1 
cells with knockdown but were increased to 1000% in 
Patu-8988, 246% in MIA Paca-2 and 160% in PANC-1 
with overexpression. A similar pattern was observed by 
qRT-PCR (Fig.  3a). When HNRNPA2B1 was knocked 
down, the messenger RNA (mRNA) and protein levels 
of CDH1 (E-cadherin) increased, whereas these levels 
were decreased when HNRNPA2B1 was overexpressed 
(Fig. 3b). As expected, N-cadherin (Fig. 3c) and vimentin 
(Fig.  3d) showed trends opposite to that of E-cadherin. 
Furthermore, we confirmed that lower HNRNPA2B1 
expression corresponded with higher E-cadherin expres-
sion and lower N-cadherin and vimentin expression in 
pancreatic cancer cells.
What’s more, we treated Patu-8988 cells with gemcit-
abine in 40, 80 and 160  µmol/L tentatively, and found 
the inhibiting effect of 160 μmol/L group is the strongest 
(Fig.  7a). Then, we respectively treated Patu-8988-OH, 
Panc-1-OH and MIA Paca-2-OH cells with gemcitabine 
in 160 μmol/L and discovered gemcitabine could inhibite 
EMT similar to HNRNPA2B1 (Fig. 7b, e). In conclusion, 
HNRNPA2B1 could regulated cell viability, EMT and the 
pharmacal sensitivity.
HNRNPA2B1 promoted invasion in pancreatic carcinoma 
cell lines
Because of the biological phenotype resulting from EMT, 
we evaluated the capacity of cells to invade to confirm 
whether HNRNPA2B1 is directly or indirectly associated 
with EMT. As shown by Fig.  4c and d, transwell inva-
sion assays indicated a decrease in the invasion rate of 
KH cells but an increase in the invasion rate of OH cell. 
According to the results, HNRNPA2B1 could stimulate 
cell invasion after accelerating the development of EMT.
We also tested expression of MMPs under differ-
ent conditions because MMPs enhance cell invasion by 
degrading the extracellular matrix. qRT-PCR and West-
ern blotting showed significant decreases in the cel-
lular levels of Mmp7 (Fig. 4a) and Mmp9 (Fig. 4b) after 
HNRNPA2B1 knockdown and increases after HNRN-
PA2B1 overexpression. These results are consistent with 
the invasion results.
Furthermore, we established xenografted tumor in 
nude mouse via subcutaneous injection of 1  ×  107 
PANC-1, PANC-1-KH and PANC-1-OH cells per mouse 
severally. As shown by Fig.  5a–c, we observed that the 
largest tumor volume and the thinnest in the PANC-1-
OH-mice but an antipodal phenomenon in the PANC-
1-KH-mice. Also, we found the tumor inhibitory rate of 
the PANC-1-KH group is the highest by using the PANC-
1-OH group as a reference substance due to its high-
est expression of HNRNPA2B1 (Fig. 5d). These data are 
consistent with that HNRNPA2B1 could stimulate the 
growth and invasion in pancreatic cancer.
HNRNPA2B1 regulated EMT progression via the ERK/snail 
pathway in pancreatic cancer cell lines
Splicing factor hnRNP A2 has been shown to activate the 
RAS-MAPK-ERK pathway by integrating A-RAF splic-
ing signalling [18]. In addition, ERK activation mark-
edly up-regulates expression of snail, one of the main 
transcription factors influencing EMT [19–25]. When 
HNRNPA2B1 was knocked down, snail expression was 
decreased according to both qRT-PCR and Western 
blotting (Fig.  6c), and that p-ERK1/2 expression was 
decreased according to Western blotting (Fig. 6b). In con-
trast, nonphosphorylated ERK1/2 remained at a higher 
level (Fig.  6a). The results obtained when HNRNPA2B1 
was overexpressed were opposite to the results obtained 
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when HNRNPA2B1 was knocked down. And then we 
respectively treated Patu-8988-OH, Panc-1-OH and MIA 
Paca-2-OH cells with ERK inhibitor, we observed that 
EMT was inhibited in the treated groups comparing with 
control groups (Fig.  7c, d, f ). Therefore, we tentatively 
conclude that HNRNPA2B1 regulates EMT progression 
via the ERK/snail pathway in pancreatic cancer cell lines.
Discussion
Pancreatic cancer, which currently has the worst progno-
sis, is the most common malignant tumour of the diges-
tive system and among the top ten malignant tumours 
in our country [26]. Although surgery is the only radical 
treatment presently available, the curative rate of pancre-
atic cancer remains very low because surgery is often no 
longer an option at the time of diagnosis [27]. Accord-
ingly, biotherapy treatments have become more popular 
over the past few years. Encouraging results have been 
reported by recent studies showing that pancreatic carci-
noma could be inhibited by controlling several biomark-
ers such as SMAD4, CXCR2, ABCG2 and Kras [28–34]. 
In addition, Barcelo et  al. showed that HNRNPA2B1 
interacts with and regulates oncogenic Kras in pancreatic 
ductal adenocarcinoma cells, and Tauler et  al. indicated 
Fig. 1 HNRNPA2B1 improves cell viability, and its expression was associated with EMT markers in pancreatic cancer cell lines. The mRNA expression 
levels of HNRNPA2B1 and EMT representative markers (E-cadherin and N-cadherin) in Panc-1 and Patu-8988 pancreatic cancer cells are presented as 
a histogram (a); HNRNPA2B1, E-cadherin, N-cadherin and vimentin were visualised by Western blotting (b); data represent the mean ± SEM, n = 3, 
*denotes P < 0.05 vs Patu-8988 groups. Fold change in cell viability of Patu-8988, PANC-1 and MIA Paca-2 cells (c); data represent the mean ± SEM, 
n = 3, *denotes P < 0.05 vs NC groups, **denotes P < 0.05 vs Patu-8988 cells, ***denotes P < 0.05 vs Panc-1 cells, #means P > 0.05 vs NC groups
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Fig. 2 HNRNPA2B1 changes cell cycle in pancreatic cancer cell lines. The cell cycle of normal pancreatic cancer cell lines (Patu-8988, MIA Paca-2 and 
PANC-1) and its treated cells were visualised by flow cytometry (a). And a histogram of the proportion for cell cycle were drew in b. Data represent 
the mean ± SEM, n = 3, *denotes P < 0.05 vs NC groups, #denotes P > 0.05 vs NC groups
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that HNRNPA2B1 modulates EMT in lung cancer cell 
lines [17, 35]. However, a clear relationship between 
HNRNPA2B1 and EMT in pancreatic cancer and the sig-
nalling pathway involved remain elusive.
We previously discovered that the level of HNRN-
PA2B1 expression is higher in pancreatic cancer than in 
non-lesion tissue, as are other cancers, such as lung can-
cer [36], hepatocellular carcinoma [16] and glioblastoma 
[37]. Based on our study, we chose several pancreatic car-
cinoma cell lines to simulate different types of pancreatic 
cancers and generated models of HNRNPA2B1 depletion 
and overexpression using Crispr/Cas9 genetic technol-
ogy. Unsurprisingly, conforming to the manifestation 
of an oncogene, both the mRNA and protein levels of 
HNRNPA2B1 were closely related with EMT, which plays 
an important role in the invasion and metastasis of can-
cer cells [38, 39]. Moreover, we found that the ERK/snail 
signalling pathway, regulated by HNRNPA2B1, plays a 
crucial role in pancreatic carcinoma.
EMT has a vital function in the process of phenotypic 
conversion [15, 40–42]. Accumulating experimental 
evidence suggests that many pancreatic cancer cell lines 
express higher levels of mesenchymal biomarkers, such 
as vimentin and N-cadherin, and lower levels of epithe-
lial biomarkers, such as E-cadherin, than normal pancre-
atic cell lines. In our study, we found that the cell lines 
expressing higher levels of HNRNPA2B1 had enhanced 
invasive and migration capacities as well as lower expres-
sion of E-cadherin and higher expression of vimentin 
and N-cadherin than the others cells. Moreover, we 
detected levels of MMP7 and MMP9 expression and 
found that HNRNPA2B1 promoted expression of these 
MMPs, with a correlated change in of MMP expressions 
and EMT development. In addition, transwell invasive-
ness assays showed a greater number of cells passing 
through the membrane when MMP levels were higher 
due to extracellular matrix degradation. What’s more, 
vivo study showed that the cells with higher expression 
of HNRNPA2B1 could induce bigger xenografted tumor 
in mice. Therefore, we speculate that HNRNPA2B1 may 
be a potent inducer of EMT in pancreatic carcinoma. 
Meanwhile, snail, an important transcription factor 
Fig. 3 HNRNPA2B1 increases EMT in pancreatic cancer cell lines. HNRNPA2B1 (a), E-cadherin (b), N-cadherin (c) and vimentin (d) were visualised by 
qRT-PCR and Western blotting (histograms of mRNA expression on pictures of protein levels). β-Actin was used as an internal control. Data repre-
sent the mean ± SEM, n = 3, *denotes P < 0.05 vs NC groups, #denotes P > 0.05 vs NC groups
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up-regulation in EMT, is noteworthy because snail trig-
gers EMT by coordinating the induction of mesenchymal 
biomarkers and the repression of epithelial biomarkers, 
which could induce EMT and promote metastasis of 
hepatocellular carcinoma. We found that the expression 
level of snail mRNA and protein consistently increased 
when HNRNPA2B1 was overexpressed. However, the 
concrete mechanism by which this occurs in pancreatic 
cancer requires further investigation.
As one of the most important intracellular pathways, 
RAS/RAF/MEK/ERK signalling causes multiple changes 
in the expression of various genes, transmitting signals 
from receptors to regulate gene expression and prevent 
apoptosis [43–46]. Recent studies have shown that activa-
tion of the ERK pathway, not only by growth factors but 
also by mutations occurring in cancer cells in the genes 
encoding RAS or RAF, contributes to EMT. RAS and 
RAF signalling also activate expression of snail1 and/
or snail2, therefore promoting cell motility and invasive 
behaviour in cancer-associated EMT [13]. Moreover, 
Hsu et  al. showed that snail promotes cell motility and 
invasive behaviour in cancer-associated EMT by activat-
ing the ERK signalling [22], HNRNPA2B1, a member of 
a heterogeneous group of nuclear ribonucleoproteins, 
has been shown to contribute to ERK activation by con-
trolling A-RAF splicing [18]. We explored the relation-
ship between snail and the ERK pathway and found that 
the expression level of snail was notably decreased with 
attenuation of ERK phosphorylation caused by HNRN-
PA2B1 knockdown. Futher more, when we inhibited the 
activation of ERK1/2, both of HNRNPA2B1 and EMT 
were decreased. Therefore, we tentatively conclude that 
HNRNPA2B1 promotes EMT by activating the ERK/
snail pathway in pancreatic cancer, revealing a potential 
Fig. 4 HNRNPA2B1 enhances cell invasion and expression of MMPs in pancreatic cancer cell lines. Mmp7 (a) and Mmp9 (b) were visualised by qRT-
PCR and Western blotting (histograms of mRNA expression on pictures of protein levels). β-Actin was used as an internal control. The cell invasion 
ability c was evaluated in normal cells, cells transfected with a negative lentivirus control and cells transfected with a lentivirus. Cells were counted 
in 3 randomised 200× fields for invasion (d). Data represent the mean ± SEM, n = 3, *denotes P < 0.05 vs NC groups, #denotes P > 0.05 vs NC 
groups
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Fig. 5 HNRNPA2B1 promotes the growth rate of xenografted tumor and decreases the weight in vivo. 1 × 107 Panc-1, Panc-1-OH and Panc-1-KH 
cells were injected in subcutaneous tissues per athymic nude mouse. Mouse were put in the blue drape for photograph on day 0, day 10 and day 
25 severally (a). The body weight (b) and tumor volume (c) of each mouse was measured and visualized as line graphs. Tumor inhibitory rate was 
calculated by using the Panc-1-OH group as a reference substance (d). Data represent the mean ± SEM, n = 3, *denotes P < 0.05 vs NC groups, 
**denotes P < 0.05 vs Panc-1-OH group
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connection between HNRNPA2B1 and EMT. Nonethe-
less, the mechanism of specific subunit by which HNRN-
PA2B1 affects the intracellular RAS/RAF/MEK/ERK 
cascade is still unknown, and the mechanism by which 
HNRNPA2B1 transfers a signal to various pathways and 
which subunits are involved requires further investigation.
Fig. 6 HNRNPA2B1promotes EMT via ERK/snail signalling in pancreatic cancer cell lines. Nonphosphorylated ERK1/2 (a), phospho-ERK1/2 (b) and 
snail (c) were visualised by qRT-PCR and Western blotting (histograms of mRNA expression on pictures of protein levels). β-Actin was used as an 
internal control. Data represent the mean ± SEM, n = 3, *denotes P < 0.05 vs NC groups, #denotes P > 0.05 vs NC groups
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Fig. 7 ERK inhibitor and gemcitabine inhibite HNRNPA2B1 and EMT in pancreatic cancer cell lines. The expression of HNRNPA2B1 in Patu-8988 cells 
treated with gemcitabine in 40, 80 and 160 μmol/L were visualised by Western blotting (a). The expression of HNRNPA2B1, E-cadherin, N-cadherin, 
Vimentin, ERK1/2, p-ERK1/2 and snail in Patu-8988-OH, Panc-1-OH and MIA Paca-2-OH cells treated with gemcitabine in 160 μmol/L were visualised 
by qRT-PCR (e) and Western blotting (b). The expression of HNRNPA2B1, E-cadherin, N-cadherin, Vimentin, ERK1/2, p-ERK1/2 and snail in Patu-
8988-OH, Panc-1-OH and MIA Paca-2-OH cells treated with ERK inhibitor were visualised by qRT-PCR (c, d) and Western blotting (f). β-Actin was used 
as an internal control. Data represent the mean ± SEM, n = 3, *denotes P < 0.05 vs control groups
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Conclusion
In summary, our study shows that via ERK/snail path-
way, HNRNPA2B1 might increase invasion ability by 
activating EMT phenotypes in pancreatic cancer. Our 
results not only provide a basis for establishing HNRN-
PA2B1-targeted molecular therapy in pancreatic cancer 
but also enrich the current understanding of HNRN-
PA2B1’s regulation of EMT and its potential signalling 
pathway.
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